Insider Selling: Vir Biotechnology, Inc. (NASDAQ:VIR) EVP Sells 1,403 Shares of Stock

Vir Biotechnology, Inc. (NASDAQ:VIR) EVP Verneuil Vanina De sold 1,403 shares of the company’s stock in a transaction dated Friday, November 1st. The stock was sold at an average price of $7.20, for a total transaction of $10,101.60. Following the sale, the executive vice president now directly owns 63,717 shares of the company’s stock, valued at $458,762.40. This represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.

Verneuil Vanina De also recently made the following trade(s):

• On Tuesday, November 5th, Verneuil Vanina De sold 2,347 shares of Vir Biotechnology stock. The shares were sold at an average price of $9.47, for a total transaction of $22,226.09.

Vir Biotechnology Trading Up 2.9 %

VIR traded up $0.27 on Tuesday, reaching $9.64. The stock had a trading volume of 1,110,639 shares, compared to its average volume of 1,024,860. The company has a market capitalization of $1.32 billion, a price-to-earnings ratio of -2.46 and a beta of 0.46. Vir Biotechnology, Inc. has a fifty-two week low of $7.12 and a fifty-two week high of $13.09. The firm has a 50-day moving average of $7.77 and a 200-day moving average of $8.88.

Vir Biotechnology (NASDAQ:VIR) last posted its earnings results on Thursday, October 31st. The company reported ($1.56) EPS for the quarter, missing the consensus estimate of ($1.05) by ($0.51). Vir Biotechnology had a negative return on equity of 36.71% and a negative net margin of 678.40%. The business had revenue of $2.38 million for the quarter, compared to analyst estimates of $5.54 million. During the same quarter in the prior year, the business earned ($1.22) earnings per share. The firm’s quarterly revenue was down 9.8% on a year-over-year basis. Sell-side analysts anticipate that Vir Biotechnology, Inc. will post -3.26 EPS for the current fiscal year.

Hedge Funds Weigh In On Vir Biotechnology

Hedge funds have recently modified their holdings of the business. Texas Permanent School Fund Corp boosted its holdings in Vir Biotechnology by 1.4% in the first quarter. Texas Permanent School Fund Corp now owns 74,977 shares of the company’s stock valued at $760,000 after acquiring an additional 1,012 shares during the last quarter. Louisiana State Employees Retirement System increased its position in shares of Vir Biotechnology by 2.8% during the second quarter. Louisiana State Employees Retirement System now owns 43,800 shares of the company’s stock worth $390,000 after buying an additional 1,200 shares during the period. ProShare Advisors LLC lifted its holdings in Vir Biotechnology by 8.4% in the first quarter. ProShare Advisors LLC now owns 26,392 shares of the company’s stock valued at $267,000 after buying an additional 2,035 shares during the period. Blue Trust Inc. lifted its holdings in Vir Biotechnology by 143.5% in the third quarter. Blue Trust Inc. now owns 3,989 shares of the company’s stock valued at $30,000 after buying an additional 2,351 shares during the period. Finally, Zurcher Kantonalbank Zurich Cantonalbank boosted its position in Vir Biotechnology by 15.0% during the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 24,647 shares of the company’s stock valued at $219,000 after acquiring an additional 3,215 shares during the last quarter. Institutional investors and hedge funds own 65.32% of the company’s stock.

Analyst Ratings Changes

Several brokerages have commented on VIR. Needham & Company LLC restated a “buy” rating and set a $19.00 price objective on shares of Vir Biotechnology in a research report on Friday. HC Wainwright restated a “buy” rating and set a $110.00 price objective on shares of Vir Biotechnology in a research report on Monday. Finally, Barclays decreased their target price on Vir Biotechnology from $28.00 to $26.00 and set an “overweight” rating on the stock in a research report on Monday. Two investment analysts have rated the stock with a hold rating and three have given a buy rating to the stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $36.40.

About Vir Biotechnology

Vir Biotechnology, Inc, an immunology company, develops therapeutic products to treat and prevent serious infectious diseases. Its clinical development pipeline consists of product candidates targeting hepatitis delta virus (HDV), hepatitis B virus (HBV), and human immunodeficiency virus (HIV). The company’s preclinical candidates include those targeting influenza A and B, coronavirus disease 2019, respiratory syncytial virus (RSV) and human metapneumovirus (MPV), and human papillomavirus (HPV).